CLEARMIND MEDICINE INC

CMNDNASDAQ

🏆 #4291 by market capUS Equity

$1.62▼ $0.01 (−0.61%)

Market closed · at close

1h—

24h▼ 0.6%

7d▼ 8.0%

14d▲ 12.5%

30d▼ 19.0%

1y▼ 99.6%

🏦Market Cap

$2M

Small Cap

📈Revenue Growth (YoY)

+0.0%

Slowing

📊Gross Margin

0.0%

Thin

💵FCF Margin

0.0%

Thin

⚖️P/S Ratio

0.0x

Cheap

Otter Score

Fair

Trading Snapshot

Day Range: $1.61 – $1.64
52-Week Range: $1.43 – $524.00
Volume: $3.30B
Avg Volume: $3.08B
Shares Outstanding: 1.5M
Next Earnings: Sep 13, 2026

Fundamentals Snapshot

Annual Revenue: $891,330
Last Q Revenue: $247,873
P/E Ratio: -0.1
P/S Ratio: 0.0x
EPS (TTM): $-26.17
Dividend Yield: 0.00%

Why Investors Own CMND

✓High-growth profile — revenue up +7.9% YoY with expanding US Equity exposure.
✓Healthy economics — 63% gross margin and 17% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$891,330▲ +10.2% YoY

Gross Margin (TTM)

62.7%▲ +4.3% YoY

Operating Income (TTM)

$272,747▲ +10.2% YoY

Free Cash Flow (TTM)

$148,852▲ +10.2% YoY

About CLEARMIND MEDICINE INC

Clearmind Medicine Inc. is a pre-clinical biopharmaceutical company dedicated to pioneering the development of novel psychedelic-based treatments. Their primary goal is to address a variety of mental health and addiction challenges that currently lack adequate solutions. The company's research targets conditions such as alcohol use disorder (including problematic binge drinking), various eating disorders (like binge eating), depression, and other compulsive or "binge" behaviors. Founded in 2017, the company initially operated under the name Cyntar Ventures Inc. before officially rebranding as Clearmind Medicine Inc. in March 2021. Its operations are headquartered in Vancouver, Canada.

🦦